Cellectar Biosciences/$CLRB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cellectar Biosciences
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
- Ticker
- $CLRB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 11
- Headquarters
- Florham Park, United States
- Website
- www.cellectar.com
CLRB Metrics
BasicAdvanced
$11M
-
-$2.71
-
-
Price and volume
Market cap
$11M
52-week high
$4.70
52-week low
$1.11
Average daily volume
145K
Financial strength
Current ratio
4.435
Quick ratio
4.24
Long term debt to equity
0.068
Total debt to equity
0.068
Profitability
EBITDA (TTM)
-26.629
Management effectiveness
Return on assets (TTM)
-75.46%
Return on equity (TTM)
-162.63%
Valuation
Price to book
0.54
Price to tangible book (TTM)
0.54
Price to free cash flow (TTM)
-0.469
Free cash flow yield (TTM)
-213.13%
Free cash flow per share (TTM)
-2.579
Growth
Earnings per share change (TTM)
-72.26%
3-year earnings per share growth (CAGR)
-72.07%
What the Analysts think about CLRB
Analyst ratings (Buy, Hold, Sell) for Cellectar Biosciences stock.
Analyst projections of the future price of Cellectar Biosciences stock.
CLRB Financial Performance
Revenues and expenses
CLRB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.